ROVI Pharmaceuticals Laboratories 
Welcome,         Profile    Billing    Logout  
 4 Products   41 Diseases   4 Products   152 Trials   6863 News 


«12345678910111213...8889»
  • ||||||||||  Darzalex (daratumumab) / J&J, Soliris (eculizumab) / AstraZeneca, Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Clinical, Review, Journal:  Advances in understanding and managing pediatric heart failure and transplant. (Pubmed Central) -  Sep 10, 2024   
    The problem of the highly sensitized transplant recipient remains, although novel therapeutics have been added to our toolbox of options to maintain healthy allograft function. Ongoing research aims to further enhance our understanding and management of pediatric heart failure, emphasizing the need for continued innovation in this complex field.
  • ||||||||||  Darzalex (daratumumab) / J&J, Soliris (eculizumab) / AstraZeneca, Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Clinical, Journal:  Advances in understanding and managing pediatric heart failure and transplant. (Pubmed Central) -  Sep 10, 2024   
    The problem of the highly sensitized transplant recipient remains, although novel therapeutics have been added to our toolbox of options to maintain healthy allograft function. Ongoing research aims to further enhance our understanding and management of pediatric heart failure, emphasizing the need for continued innovation in this complex field.
  • ||||||||||  Fragmin (dalteparin sodium) / Pfizer, Eisai, Hibor (bemiparin) / ROVI Pharmaceuticals Laboratories, Elder Pharma
    Review, Journal:  Exploring the use of electroconvulsive therapy in the anticoagulated population: A systematic review. (Pubmed Central) -  Sep 10, 2024   
    This review showed tolerability of anticoagulants continued throughout electroconvulsive therapy, with most patients reporting no adverse effects. Given limitations including few studies and medical comorbidities influencing patient risk profile, further studies are required to guide practice recommendations and review long-term outcomes.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Characteristics Of Patients Eligible For Sacubitril Valsartan Optimization (Exhibit Hall C - ePoster Hub; Monitor 14) -  Sep 3, 2024 - Abstract #HFSA2024HFSA_606;    
    170 patients had a documented allergy to ACE, ARB, or ARNI and were excluded. 324 patients were on an ACE or ARB and 186 patients were not on any medications.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Effects Of Angiotensin-Neprilysin Inhibition In Women Versus Men With Mildly Reduced Or Preserved Ejection Fraction And Worsening Heart Failure: Insights From PARAGLIDE-HF (Exhibit Hall C - ePoster Hub; Monitor 25) -  Sep 3, 2024 - Abstract #HFSA2024HFSA_593;    
    In the overall study population, time-averaged reduction in NT-proBNP was significantly greater for Sacubitril-Valsartan (Sac/Val) than Valsartan (ratio of change 0.85; 95% CI:0.73-0.999)...In the overall study population, time-averaged reduction in NT-proBNP was significantly greater for Sacubitril-Valsartan (Sac/Val) than Valsartan (ratio of change 0.85; 95% CI:0.73-0.999)... The efficacy, safety and tolerability of Sac/Val versus Valsartan were similar in both men and women in the PARAGLIDE-HF trial.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
     (Room: Georgia World Congress Center - C102) -  Sep 3, 2024 - Abstract #HFSA2024HFSA_574;    
    In this comparative analysis, medication adherence patterns and pharmacotherapy clinic utilization among heart failure patients under the care of APRN were explored with a focus on three key medications: Entresto, Jardiance, and Farxiga. The findings shed light on critical aspects of patient management and treatment optimization, despite variations in patients
  • ||||||||||  acoramidis (AG10) / BridgeBio, Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Contemporary Oral Medication Usage And Frequency In Patients With Transthyretin Cardiac Amyloidosis (Exhibit Hall C - ePoster Hub; Monitor 11) -  Sep 3, 2024 - Abstract #HFSA2024HFSA_494;    
    Pts with ATTR-CM take multiple oral medications administered BID for treatment of HF and other comorbidities. As a BID medication, acoramidis, an investigational, novel treatment for ATTR-CM with robust efficacy on CVH, fits in their current medication dosing schedule.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Effect Of Sacubitril-Valsartan On Heart Failure Biomarkers: A Long-Term Retrospective Analysis (Exhibit Hall C - ePoster Hub; Monitor 07) -  Sep 3, 2024 - Abstract #HFSA2024HFSA_373;    
    NT proBNP did not show differences in levels in ICM and NICM. sST2 and galectin-3 showed significant differences in levels between the ICM and NICM subgroups possibly to differences in the levels of fibrosis in the two groups.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    Severe Early Onset Dilated Cardiomyopathy Associated With A Novel Tnn13 Gene Mutation (Exhibit Hall C - ePoster Hub; Monitor 11) -  Sep 3, 2024 - Abstract #HFSA2024HFSA_343;    
    Interestingly, his LV dilation has not been associated with any LGE on imaging nor any atrial or ventricular arrhythmias while his father has had significant PVCs and less LV dilation. To our knowledge, this is the first report of the TNNI3 c.12-1G>A mutation and represents an important addition to the literature and testing armamentarium for cardiovascular genetics.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    Pharmacist-led Guideline-directed Medical Therapy (GDMT) Clinic For The Optimization Of Medications For Heart Failure With Reduced Ejection Fraction (Exhibit Hall C - ePoster Hub; Monitor 30) -  Sep 3, 2024 - Abstract #HFSA2024HFSA_235;    
    A pharmacist-led GMDT titration clinic within a HF clinic led to increased number of patients achieving target doses of medications within 12 weeks with significant improvement in EF. Further studies will explore comparisons with standard office visits and implications for best practices for HF management.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Journal, Adverse events, Real-world evidence, Real-world:  A real-world disproportionality analysis of sacubitril/valsartan: data mining of the FDA adverse event reporting system. (Pubmed Central) -  Aug 28, 2024   
    Notably, this study also discovered a high frequency of side effects such as death, dyspnea, weight change, feeling abnormal, hearing loss, memory impairment, throat clearing, and diabetes mellitus. This study identified potential new AE signals and gained a more general understanding of the safety of sacubitril/valsartan, promoting its rational adoption in the cardiovascular system.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Review, Journal:  Possible role of LCZ696 in atherosclerosis: new inroads and perspective. (Pubmed Central) -  Aug 21, 2024   
    In conclusion, LCZ696 could be effective in the management of AS through modulation of inflammatory and oxidative signaling. Preclinical and clinical studies are recommended in this regard.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, GSK4024484 / GSK
    Journal:  Von Willebrand factor exacerbates heart failure through formation of neutrophil extracellular traps. (Pubmed Central) -  Aug 21, 2024   
    This study established the role of a novel VWF-SLC44A2-NET axis in regulating mitochondrial homeostasis and function, leading to cardiac apoptosis and contributing to HF pathogenesis. Targeting this axis may offer a potential therapeutic approach for HF treatment.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Clinical, Retrospective data, Journal:  Sacubitril-Valsartan in Patients Requiring Hemodialysis. (Pubmed Central) -  Aug 20, 2024   
    Only 195 participants (14%) ever received the maximum combination dose of sacubitril (97 mg twice daily) and valsartan (103 mg twice daily). In this comparative effectiveness study of patients with HFrEF requiring hemodialysis, sacubitril-valsartan therapy was associated with beneficial effects in all-cause mortality and all-cause hospitalization.
  • ||||||||||  colchicine / Generic mfg.
    Rhabdomyolysis with Diarrhea: A Rare Case of Colchicine Toxicity (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_4264;    
    Home medication included Entresto 49-51 mg, Farxiga 10 mg, aspirin 81 mg, clopidogrel 75 mg, metoprolol 25 mg, Eliquis 5 mg BID, amiodarone 200 mg, colchicine 0.6 mg BID...Patient was started on mirtazapine for decreased appetite...The majority of negative effects subside after cessation. This case highlights the need to consider medication side effects should be kept in mind when patients present with non-specific complaints not pertaining to a particular disease group.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Isolated Cecal Ischemia Presenting as a Mass: A Case Report (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_2480;    
    Figure: Image A- CT angiogram of the abdomen and pelvis showing a possible cecal mass with wall thickening and irregularity as well as infiltration of the adjacent fat with a few nodes. Images B and C- Inpatient colonoscopy showing a severely friable and edematous mucosa with ulcerated mass like appearance of a portion of the cecum
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Contrave (naltrexone/bupropion) / Currax, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
    Analysis of Provider Preferences for AI-Generated Responses to Anti-Obesity Treatments (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_1952;    
    FDA provided responses were significantly shorter (99 words) than those of either Gemini (186 words) or GPT-4 (252 words), p< 0.001. 85% of all responses were deemed accurate, and there was no significant difference between LLM and FDA responses.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Trial completion date, Trial primary completion date:  Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition (clinicaltrials.gov) -  Aug 14, 2024   
    P3,  N=25, Suspended, 
    In patients with HFrEF and concomitant significant MR, treatment with sacubitril/valsartan was associated with lower risks of all-cause death. Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Jun 2026
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Reimbursement, US reimbursement, Journal, Medicare, Adherence:  Trajectories of Sacubitril/Valsartan Adherence Among Medicare Beneficiaries With Heart (Pubmed Central) -  Aug 12, 2024   
    Half of ARNi users were not consistently adherent to the drug in the first year after treatment initiation. There exist significant racial and socioeconomic inequities in longitudinal adherence to ARNi.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Journal:  Novel Initiative Increasing GDMT Use Among Patients With Heart (Pubmed Central) -  Aug 7, 2024   
    Following project implementation, ARNI utilization rose from 31% to 67% and MRA increased from 28% to 66%. Establishing clear quality metrics and formulating a proactive evaluation process was associated with a significant increase in prescription rates.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Journal, Adverse events:  Pseudo-nephropathy and hyper-excretion of urinary C-peptide: an overlooked adverse effect of an angiotensin receptor-neprilysin inhibitor (ARNI). (Pubmed Central) -  Aug 5, 2024   
    Sacubitril/valsartan, which is a combined angiotensin receptor-neprilysin inhibitor (ARNI), is used for the treatment of chronic heart failure and hypertension...Therefore, increased glomerular permeability and filtration could partially explain how neprilysin inhibition led to an elevation in UCPR excretion, in addition to other mechanisms, such as impairment of the renal ability to degrade C-peptide. Physicians must be cautious when interpreting the insulin secretion capability by UCPR and nephropathy by UAlb in ARNI-treated patients with diabetes.
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Enrollment status, Trial completion date, Trial primary completion date:  PDD in Type 2 Diabetes w/wo Diastolic Dysfunction (clinicaltrials.gov) -  Aug 5, 2024   
    P2,  N=80, Enrolling by invitation, 
    Physicians must be cautious when interpreting the insulin secretion capability by UCPR and nephropathy by UAlb in ARNI-treated patients with diabetes. Recruiting --> Enrolling by invitation | Trial completion date: Jun 2024 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Dec 2024
  • ||||||||||  Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
    Trial completion date:  The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans (clinicaltrials.gov) -  Aug 4, 2024   
    P4,  N=90, Active, not recruiting, 
    Recruiting --> Enrolling by invitation | Trial completion date: Jun 2024 --> Mar 2025 | Trial primary completion date: Jun 2024 --> Dec 2024 Trial completion date: Jun 2024 --> Jun 2025